Long‐acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta‐analysis
- 24 February 2009
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (4), 372-378
- https://doi.org/10.1111/j.1463-1326.2008.00976.x
Abstract
Basal insulin in type 1 diabetes can be provided using either NPH (Neutral Protamine Hagedorn) human insulin or long-acting insulin analogues, which are supposed to warrant a better metabolic control with reduced hypoglycaemic risk. Aim of this meta-analysis is the assessment of differences with respect to HbA1c (Glycated hemoglobin), incidence of hypoglycaemia, and weight gain, between NPH human insulin and each long-acting analogue.Of 285 randomized controlled trials with a duration > 12 weeks comparing long-acting insulin analogues (detemir or glargine) with NPH insulin in type 1 diabetic patients identified through Medline search and searches on www.clinicaltrials.gov, 20 met eligibility criteria (enrolling 3693 and 2485 in the long-acting analogues and NPH group respectively). Data on HbA1c and body mass index at endpoint, and incidence of any, nocturnal and severe hypoglycaemia, were extracted and meta-analysed.Long-acting analogues had a small, but significant effect on HbA1c [-0.07 (-0.13; -0.01)%; p = 0.026], in comparison with NPH human insulin. When analysing the effect of long-acting analogues on body weight, detemir was associated with a significantly smaller weight gain than human insulin [by 0.26 (0.06;0.47) kg/m2; p = 0.012]. Long-acting analogues were associated with a reduced risk for nocturnal and severe hypoglycaemia [OR (Odd Ratio, 95% Confidence Intervals) 0.69 (0.55; 0.86), and OR 0.73 (0.60; 0.89) respectively; all p < 0.01].The switch from NPH to long-acting analogues as basal insulin replacement in type 1 diabetic patients had a small effect on HbA1c, and also reduced the risk of nocturnal and severe hypoglycaemia.This publication has 26 references indexed in Scilit:
- A Randomized, Controlled Trial Comparing Twice-a-Day Insulin Glargine Mixed With Rapid-Acting Insulin Analogs Versus Standard Neutral Protamine Hagedorn (NPH) Therapy in Newly Diagnosed Type 1 DiabetesPEDIATRICS, 2008
- Novo Nordisk ASPharmaDeals Review, 2008
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes MellitusClinical Therapeutics, 2007
- Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetesDiabetic Medicine, 2007
- Assessing glycemia in type 1 diabetic patients using a microdialysis system for continuous glucose monitoringAnnals of Saudi Medicine, 2007
- Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemirCurrent Medical Research and Opinion, 2006
- Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetesDiabetic Medicine, 2006
- Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents with Type I Diabetes MellitusJournal of Pediatric Endocrinology and Metabolism, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996